About Tumor necrosis factor ligand superfamily member 14
Tumor necrosis factor ligand superfamily member 14 (TNFSF14) is a protein
from Homo sapiens identified by UniProt accession
O43557, 240 residues long.
MolForge cross-references it against 0 known binders and
427 disease associations.
Target properties
| Protein name | Tumor necrosis factor ligand superfamily member 14 |
|---|
| UniProt accession | O43557 |
|---|
| Gene | TNFSF14 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 240 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (427)
Diseases linked to this target (Open Targets).
- monocyte count · score 0.42
- serum gamma-glutamyl transferase measurement · score 0.42
- tumor necrosis factor ligand superfamily member 14 measurement · score 0.39
- blood protein measurement · score 0.37
- leukocyte count · score 0.35
- multiple sclerosis · score 0.35
- lymphocyte count · score 0.31
- monocyte percentage of leukocytes · score 0.31
- myeloid white cell count · score 0.22
- granulocyte percentage of myeloid white cells · score 0.21
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O43557-F1 | alphafold | PREDICTED | 84.33 | — |
Amino-acid sequence (240 residues)
MEESVVRPSV FVVDGQTDIP FTRLGRSHRR QSCSVARVGL GLLLLLMGAG LAVQGWFLLQ LHWRLGEMVT RLPDGPAGSW EQLIQERRSH EVNPAAHLTG ANSSLTGSGG PLLWETQLGL AFLRGLSYHD GALVVTKAGY YYIYSKVQLG GVGCPLGLAS TITHGLYKRT PRYPEELELL VSQQSPCGRA TSSSRVWWDS SFLGGVVHLE AGEKVVVRVL DERLVRLRDG TRSYFGAFMV
Explore Tumor necrosis factor ligand superfamily member 14 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets